Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in PGNMID
NCT05654506Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2023
- Primary completion
- Aug 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), sponsored by Mayo Clinic. Primary endpoint: Change in proteinuria at 12 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID)
Beyond the preview
Go deeper on NCT05654506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654506.